Nirrin, a company focused on advancing bioprocess analytics with high-precision tunable laser spectroscopy, has secured $6.7M in Series A funding. The investment highlights the company's approach to delivering direct, quantitative measurements from development through manufacturing.
Nirrin's TALOS™ system provides rapid protein quantitation without dilution or calibration curves, while its ATLAS® platform enables multi-analyte measurement of proteins, buffers, and excipients in complex bioprocess and formulation samples. The systems are designed to help bioprocess teams generate trustworthy data, simplify workflows, and make better manufacturing decisions.
